An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

Summary

The purpose of this EAP is to provide expanded access (i.e., before marketing authorization) to vusolimogene oderparepvec (VO; herein referred to as VO) plus standard-of-care (SOC), nivolumab, for eligible patients diagnosed with advanced melanoma, who, in their treating physician's opinion, could benefit from this treatment.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications